Growing use of GLP-1s has reduced demand for bariatric surgery across U.S. hospitals. We’ve developed three scenarios to predict how GLP-1s will further reduce bariatric surgery volumes over the next five years. The extent of this decline, ranging from -15% to -33%, hinges on how market conditions impact GLP-1 use rates among U.S. adults. Read on to find out which scenario we believe is most likely and what conditions will influence variation across markets.